Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$68.04 USD
-0.08 (-0.12%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $68.04 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.04 USD
-0.08 (-0.12%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $68.04 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
Zacks News
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
Are Medical Stocks Lagging AC Immune (ACIU) This Year?
by Zacks Equity Research
Here is how AC Immune (ACIU) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
Exact Sciences (EXAS) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.
MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More
by Urmimala Biswas
MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.
Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts
by Zacks Equity Research
Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
by Zacks Equity Research
Here is how Exact Sciences (EXAS) and Anebulo Pharmaceuticals, Inc. (ANEB) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Adobe, S&P Global, Arista Networks, Cincinnati Financial and Exact Sciences
by Zacks Equity Research
Adobe, S&P Global, Arista Networks, Cincinnati Financial and Exact Sciences are included in this Analyst Blog.
Top Research Reports for Adobe, S&P Global & Arista Networks
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Adobe Inc. (ADBE), S&P Global Inc. (SPGI) and Arista Networks, Inc. (ANET).
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Exact Sciences (EXAS) Gains From New Buyouts Amid Rising Costs
by Zacks Equity Research
Exact Sciences (EXAS) is improving customer experience by making it simpler to order Cologuard electronically and continue re-screening of patients every three years.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS), backed by Cologuard growth and upbeat guidance.
Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH
by Zacks Equity Research
Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PRFZ
Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View
by Zacks Equity Research
Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.
Here's What Key Metrics Tell Us About Exact Sciences (EXAS) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Exact Sciences (EXAS) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 10% and 3.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.